Market Overview

Healionics welcomes new board director Ryan Takeuchi

Share:

Healionics welcomes new board director Ryan Takeuchi

PR Newswire

SEATTLE, Aug. 29, 2018 /PRNewswire/ -- Healionics Corporation, a Seattle-based medical device company, has announced the addition of Ryan Takeuchi to its board of directors.

Healionics is addressing the critical need for improved means of dialysis access in patients with kidney failure.  Its STARgraft is an innovative vascular graft (synthetic blood vessel). The company also has an exciting product pipeline, based on its platform STAR biomaterial technology. STAR biomaterial is already in human use as a commercial implant for glaucoma treatment, and has shown promising preclinical results for a wide variety of other implantable applications. www.healionics.com

Takeuchi brings 20 years of experience in medical devices and private equity, and most recently served as divisional business leader of W.L. Gore's Medical Products Division. 

"We appreciate Ryan's vote of confidence in Healionics and our market opportunity, particularly given his insight as recent head of the market leader in our industry sector," said CEO Mike Connolly.  "We're excited to have him join the board and we welcome his expertise in new product launch, global marketing, and finance/M&A."

Said Takeuchi, "Healionics' STARgraft and related future products have the potential to reduce the huge costs associated with maintaining reliable vascular access for dialysis patients and to improve the health and quality of life of these patients.  I look forward to helping the company bring these products to market."

About Healionics Corporation
Healionics is addressing the critical need for improved means of dialysis access in patients with kidney failure.  Its STARgraft is an innovative vascular graft (synthetic blood vessel) that has demonstrated much better reliability than on-market devices in multiple preclinical studies, thus offering the potential to substantially reduce cost, illness and death among dialysis patients.  The company also has an exciting product pipeline, based on its platform STAR biomaterial technology. This novel material can facilitate new types of implantable devices and improve the performance of existing ones via its unique ability to prevent both scarring and infection.  STAR biomaterial is already in human use as a commercial implant for glaucoma treatment, and has shown promising preclinical results for a wide variety of other implantable applications. www.healionics.com

 

Contact:
Julie Rathbun
Rathbun Communications, Inc.
T : +1.206.769.9219
Julie@rathbuncomm.com

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/healionics-welcomes-new-board-director-ryan-takeuchi-300704393.html

SOURCE Healionics Corporation

View Comments and Join the Discussion!